A detailed history of Royal Bank Of Canada transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 21,757 shares of DVAX stock, worth $264,782. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,757
Previous 20,900 4.1%
Holding current value
$264,782
Previous $234,000 3.42%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $11.61 $8,612 - $9,949
857 Added 4.1%
21,757 $242,000
Q2 2024

Aug 14, 2024

BUY
$10.73 - $12.58 $71,236 - $83,518
6,639 Added 46.55%
20,900 $234,000
Q1 2024

Nov 05, 2024

SELL
$11.7 - $14.98 $77,676 - $99,452
-6,639 Reduced 31.77%
14,261 $176,000
Q1 2024

May 15, 2024

SELL
$11.7 - $14.98 $380,799 - $487,554
-32,547 Reduced 69.53%
14,261 $176,000
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $192,527 - $220,325
14,708 Added 45.82%
46,808 $654,000
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $80,251 - $95,171
6,349 Added 24.66%
32,100 $474,000
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $72,811 - $97,352
7,392 Added 40.26%
25,751 $332,000
Q1 2023

May 15, 2023

SELL
$9.44 - $11.88 $117,584 - $147,977
-12,456 Reduced 40.42%
18,359 $180,000
Q4 2022

Feb 14, 2023

BUY
$10.27 - $13.29 $157,582 - $203,921
15,344 Added 99.18%
30,815 $327,000
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $162,385 - $285,196
-16,353 Reduced 51.39%
15,471 $161,000
Q2 2022

Aug 15, 2022

SELL
$7.45 - $12.83 $42,703 - $73,541
-5,732 Reduced 15.26%
31,824 $400,000
Q1 2022

May 16, 2022

SELL
$9.75 - $14.44 $17,559 - $26,006
-1,801 Reduced 4.58%
37,556 $408,000
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $43,856 - $69,730
3,330 Added 9.24%
39,357 $554,000
Q3 2021

Nov 15, 2021

BUY
$9.16 - $19.83 $162,819 - $352,478
17,775 Added 97.39%
36,027 $692,000
Q2 2021

Aug 16, 2021

BUY
$7.25 - $10.99 $132,327 - $200,589
18,252 New
18,252 $180,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.54B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.